Inventor · disambiguated record
Lilly L. Wong
Also filed as: WONG LILLY · WONG LILLY L · WONG LILLY LORAINE
11 granted patents·5 pending applications·29 citations·filing 2011–2024
86Inventor score
Top patents by PatentIndex Score
16 records- 0196US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0295US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0388US11660297B2Antiproliferative compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted May 30, 2023·2 cites·19 claims
- 0486US11726080B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2021·Granted Aug 15, 2023·1 cites·21 claims
- 0584US12510533B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2023·Granted Dec 30, 2025·0 cites·18 claims
- 0682US10969381B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2019·Granted Apr 6, 2021·1 cites·16 claims
- 0782US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 0880US12186311B2Antiproliferative compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Jan 7, 2025·0 cites·14 claims
- 0980US2025082629A1Antiproliferative compounds and second active agents for combined useCELGENE CORP·Filed 2024·Application pending·0 cites
- 1079US2024366593A1Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined useCELGENE CORP·Filed 2024·Application pending·0 cites
- 1177US12053466B2Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined useCELGENE CORP·Filed 2022·Granted Aug 6, 2024·0 cites·19 claims
- 1277US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 1371US11439637B2Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined useCELGENE CORP·Filed 2019·Granted Sep 13, 2022·0 cites·20 claims
- 1442US2013245026A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Application pending·0 cites
- 1538US10576085B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Mar 3, 2020·0 cites·22 claims
- 1637US2012028972A1Biomarker assays for detecting or measuring inhibition of tor kinase activityWONG LILLY·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lilly L. Wong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →